XORTX Therapeutics Files April 2025 6-K Report
Ticker: XRTX · Form: 6-K · Filed: Apr 30, 2025 · CIK: 1729214
Sentiment: neutral
Topics: sec-filing, 6-k, regulatory-update
TL;DR
XORTX filed its monthly 6-K, confirming 20-F annual report status.
AI Summary
XORTX Therapeutics Inc. filed a Form 6-K on April 30, 2025, reporting for the month of April 2025. The filing indicates that the company is a foreign private issuer and will file annual reports under Form 20-F. Allen Davidoff, the Chief Executive Officer, signed the report.
Why It Matters
This filing provides routine updates on the company's reporting status as a foreign private issuer, confirming their adherence to SEC regulations.
Risk Assessment
Risk Level: low — This is a routine administrative filing and does not contain new financial or operational information that would typically indicate a change in risk.
Key Players & Entities
- XORTX Therapeutics Inc. (company) — Registrant
- Allen Davidoff (person) — Chief Executive Officer
- April 30, 2025 (date) — Filing date
FAQ
What is the purpose of this Form 6-K filing?
This Form 6-K is a Report of Foreign Private Issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934, for the month of April 2025.
Which annual report form does XORTX Therapeutics Inc. file?
XORTX Therapeutics Inc. files its annual reports under cover of Form 20-F.
Who signed the Form 6-K on behalf of XORTX Therapeutics Inc.?
Allen Davidoff, Chief Executive Officer, signed the report on behalf of XORTX Therapeutics Inc.
What is the filing date of this report?
The filing date of this report is April 30, 2025.
What is the company's primary business classification?
The company's Standard Industrial Classification is Pharmaceutical Preparations [2834].
Filing Details
This Form 6-K (Form 6-K) was filed with the SEC on April 30, 2025 by Allen Davidoff regarding XORTX Therapeutics Inc. (XRTX).